

**The Michael J. Fox Foundation for Parkinson's Research**  
**Parkinson's Disease Therapeutics Conference**

New York, NY

October 29, 2014

# CONFERENCE PROGRAM

---

**8:30**                    **BREAKFAST**

---

**9:00 – 9:30**           **WELCOME BY TODD SHERER, PhD AND J. WILLIAM LANGSTON, MD**

---

**9:30 – 11:00**        **DISEASE MODIFYING THERAPIES**

**NIGEL H. GREIG, PhD, National Institute on Aging, NIH**

“DPP-4 Inhibitors for the Treatment of Parkinson's Disease”

**ALEX B. BURGIN, PhD, The Broad Institute**

“LRRK2 Biological Structure and Function”

**ACHIM SCHNEEBERGER, MD, AFFiRiS AG**

“First-in-human Trial to Assess the Safety and Tolerability of PD01A, the First Alpha-synuclein-based AFFITOPE Parkinson's Vaccine”

---

**11:00 – 11:30**       **NETWORKING BREAK/POSTER VIEWING**

---

**11:30 – 12:30**       **RESEARCH TOOLS AND RESOURCES**

**KULDIP DAVE, PhD, The Michael J. Fox Foundation for Parkinson's Research**

“Which is an Ideal Mouse Model? MJFF's Head-to-Tail Comparison of Alpha-synuclein Mouse Models”

**KENNETH MAREK, MD, The Institute for Neurodegenerative Disorders**

“Parkinson's Progression Markers Initiative: Developing Biomarkers to Accelerate PD Therapies”

---

**12:30 – 2:00**        **LUNCH/POSTER VIEWING**



**2:00 – 3:30**

## **SYMPTOMATIC THERAPIES**

**ROMULO ANTONIO FUENTES, PhD, Edmond and Lily Safra International Institute of Neuroscience of Natal**

“Validation of Dorsal Column Electrical Stimulation as a Target for Parkinson's Disease Therapy in 6-OHDA Non-human Primates”

**ROBERT JOSEPH MATHER, AstraZeneca Neuroscience**

“The Role of Nicotinic Receptors in Parkinson's Disease: The Opportunity and Challenges of Developing New Therapies”

**SHEILA OREN, MD, NeuroDerm Ltd**

“Continuous Subcutaneous Administration of Levodopa/Carbidopa (ND0612) for the Treatment of Parkinson's Disease”

---

**3:30 – 4:00**

## **NETWORKING BREAK/POSTER VIEWING**

---

**4:00 – 5:00**

## **HOT TOPICS IN PARKINSON'S DISEASE RESEARCH**

**JEFFREY H. KORDOWER, PhD, Rush University Medical Center**

“The Prion Hypothesis of Parkinson's Disease: Is it Ready for Prime Time Therapeutic Targeting?”

**RUSSELL KATZ, MD**

“PD Drug Development from the FDA's Perspective”

---

**5:00 – 5:15**

## **CLOSING REMARKS**

---

**5:15 – 7:00**

## **COCKTAIL RECEPTION/POSTER VIEWING**

